Massachusetts man with rare disease denied experimental drug treatment

“It’s been a long one,” Alexandra Eaton told WBZ-TV from her Marshfield home. “It’s been challenging, but he’s persevered.” You can see the love in Eaton’s eyes, looking at her son, whose care and comfort consumes her entire life. Josh, who is 26, lives with rare and debilitating Arginase 1 Deficiency.

Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)

Stockholm, December 18, 2023: Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human […]

Experts Implore FDA to Accept Biomarker Evidence in Ultra-Rare Diseases

By Heather McKenzie See Orignial Story Here Arginase 1 deficiency, or ARG1-D, is a rare, inherited disorder occurring in approximately 1.1 in 1 million live U.S. births. While born with normal function, by the age of two, patients with the condition have progressive deterioration in their physical ability due to the gradual accumulation of arginine and ammonia […]

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation Application for pegzilarginase is under review by the European Medicines Agency WALTHAM, Mass., July 27, […]

Skip to content